Keenova Therapeutics plc 8-K

What Happened
Keenova Therapeutics plc announced unaudited financial results for the three months ended December 31, 2025 and provided supplemental pro forma FY2025 results. The company also issued full‑year 2026 guidance and said it will file a Form 12b‑25 to delay its 2025 Form 10‑K (extended filing deadline to April 15, 2026) because of complex accounting related to its July 2025 merger with Endo and the November 2025 spin‑off.

Key Details

• 2026 guidance: net sales of $1.94 billion to $2.00 billion; Adjusted EBITDA of $730 million to $760 million.
• Product growth guidance: Acthar Gel net sales growth in the mid‑teens; XIAFLEX net sales growth in the mid‑ to high‑single digits. Aggregate XIAFLEX net sales for FY2025: $546.3 million (Endo $299.7M pre‑merger + Keenova $246.6M post‑merger).
• The guidance excludes potential acquisition/divestiture activity, including the planned divestiture of the Percocet business (expected to generate ~ $65M in net sales and ~ $64M in Adjusted EBITDA for 2026). Adjusted EBITDA is a non‑GAAP measure; no GAAP reconciliation is provided for forward‑looking Adjusted EBITDA.
• Delay in filing 2025 Form 10‑K: Keenova will file a Form 12b‑25 (filed April 1) and intends to file the Form 10‑K on or before April 15, 2026. The delay could trigger covenant defaults under its Credit Agreement (term loan outstanding $1,481.3M as of Dec 31, 2025; $400M revolver mostly undrawn) and its Indenture (8.50% Senior Secured Notes — $1,000M outstanding). If not cured within contract grace periods, lenders or noteholders could accelerate repayment; margins on term loans would increase by 25 basis points during the delay.

Why It Matters
This 8‑K combines operational guidance (sales and profitability targets for 2026) with a material disclosure about a delayed audited filing that could affect the company’s debt covenants. Investors should note the revenue and Adjusted EBITDA targets and that those figures incorporate expected merger synergies but exclude possible proceeds or results from the planned Percocet divestiture. The filing delay raises short‑term financial risk tied to covenant waivers and potential acceleration of debt if audited statements are not delivered within the specified grace periods, though the company says it intends to file before those grace periods expire.